Hanson & Doremus Investment Management Vertex Pharmaceuticals Inc Transaction History
Hanson & Doremus Investment Management
- $627 Million
- Q3 2024
A detailed history of Hanson & Doremus Investment Management transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Hanson & Doremus Investment Management holds 70 shares of VRTX stock, worth $27,954. This represents 0.01% of its overall portfolio holdings.
Number of Shares
70
Previous 70
-0.0%
Holding current value
$27,954
Previous $32,000
-0.0%
% of portfolio
0.01%
Previous 0.01%
Shares
4 transactions
Others Institutions Holding VRTX
# of Institutions
1,725Shares Held
221MCall Options Held
1.58MPut Options Held
1.36M-
Capital World Investors Los Angeles, CA26.8MShares$10.7 Billion1.99% of portfolio
-
Vanguard Group Inc Valley Forge, PA23.2MShares$9.25 Billion0.2% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$8.51 Billion0.23% of portfolio
-
State Street Corp Boston, MA11.8MShares$4.72 Billion0.23% of portfolio
-
Capital Research Global Investors Los Angeles, CA9MShares$3.6 Billion0.9% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $103B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...